Pfizer Boosts Bid for Metsera Amid Intensifying Rivalry with Novo Nordisk in Obesity Drug Market 
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment 
Parents abused by their children often suffer in silence – specialist therapy is helping them find a voice 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
U.S. Dollar Steadies Near October Lows as Rate Cut Expectations Keep Markets on Edge 
Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change 
FDA Names Tracy Beth Høeg as Acting CDER Director After Richard Pazdur Announces Retirement 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
BoE Set to Cut Rates as UK Inflation Slows, but Further Easing Likely Limited 
Canada Loses Measles-Free Status After Nearly 30 Years Amid Declining Vaccination Rates 
Canada’s local food system faces major roadblocks without urgent policy changes 
Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage 
New Zealand Business Confidence Hits 30-Year High as Economic Outlook Improves 
Disaster or digital spectacle? The dangers of using floods to create social media content 
Eli Lilly’s Weight-Loss Pill Nears Fast-Track FDA Approval as Profits Surge on Global Demand 
Coca-Cola Japan and Kirin Holdings will develop health drinks that contain the live bacteria, lactococcus lactis strain plasma (LC-Plasma), an ingredient patented by Kirin that is used in the company's health drinks.
Kirin claims that the live bacteria boosts immunity in healthy people.
Kirin is the first among companies that make foods and beverages they claim to boost immunity to have been approved by Japan's Consumer Affairs Agency in 2020 to advertise its products as such.
Coca-Cola Japan plans to put LC-Plasma into three of its brands, Georgia, Irohasu, and Minute Maid.
The Consumer Affairs Agency has also given the go-ahead for the drinks to be advertised as having the advantage.
The partnership demonstrates Coca-Cola Japan's intention to improve its position in the health beverage market. According to market research firm Inryo Soken, Coca-Cola has a 26 percent market share in soft drinks but has not advanced significantly in the market for health beverages.
On the other hand, Kirin is increasing sales of its LC-Plasma component and sees health products as its next area of growth. It anticipates that by 2027, sales of health drinks will have increased fivefold from their current level to 50 billion yen.
Taisho Pharmaceutical Holdings, as well as candy manufacturers including Morinaga & Co. and Kanro, have already purchased the component from Kirin.
Although supplying a rival with distinctive ingredients would negate Kirin's advantage, collaborating with Coca-Cola might let it expand its market.
